Skip to content
Menu

Upstream Bio, Inc. UPB

Full chart Compare
Set alert

Price alert · UPB

All alert types
1.59 USD -0.41 (-20.50%)

Regular-session close

1.59 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

1.56 Day range 2.06
1.56 52-week range 33.68
YTD
-94.14%
1 year
-93.63%

5D -0.94 (-31.02%)

22.503ThuFriMonTueWed2.09
Market cap
87.15M
Revenue (ttm)
2.85M
EPS (ttm)
-3.01
Shares out
54.04M
Forward P/E
-2.45
YTD return
-94.14%
1-year return
-93.63%
50-day average
18.55
Volume
1.39M
Avg volume
993.16K
Open
1.98
Previous close
2.00
Day's range
1.56 – 2.06
52-week range
1.56 – 33.68
Analysts
Strong Buy
Price target
47.86 (+2909.9%)

Key statistics

200-day average
19.11
Price / sales
164.16
Price / book
1.38
Revenue growth
9.00%
Total cash
341.51M
Total debt
1.27M
Return on equity
-35.44%
Short % of float
15.85%

Fundamental scorecard

4 of 25 checks passed on UPB’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
UPB Revenue — quarterly 395.00K
UPB Net income — quarterly -41.19M
UPB EPS — quarterly -0.75

Upgrades / downgrades

UPB analyst upgrades and downgrades
DateFirmActionFromTo
Mar 27, 2026Evercore ISI GroupdownOutperformIn-Line
Dec 18, 2025Mizuhoinit—Outperform
Dec 2, 2025LifeSci Capitalinit—Outperform
Nov 18, 2025Evercore ISI Groupinit—Outperform
Oct 14, 2025Truist Securitiesinit—Buy
Nov 5, 2024JP Morganinit—Overweight

About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on UPB — it syncs with the Stock Master app.

Insider holders

UPB insider holders
InsiderRelationLatest transactionDateShares held
AI UPSTREAM LLCBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityOct 14, 20240
AMBROSE ALLISONGeneral CounselSaleMar 15, 202616,525
CHIMOVITS EREZDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityOct 14, 20240
DEYKIN AARON M.D.OfficerSaleMar 15, 202632,687
GRAY MICHAEL PChief Operating OfficerSaleMar 15, 202629,648
HOUGHTON ADAMOfficerSaleMar 15, 202624,301

Institution ownership

UPB institution ownership
Holder% heldSharesValueReported
FMR, LLC13.91%7,518,20265.18MDec 30, 2025
Orbimed Advisors LLC.10.54%5,693,58949.36MDec 30, 2025
Blackrock Inc.6.19%3,344,50429.00MDec 30, 2025
Decheng Capital LLC5.82%3,143,07827.25MDec 30, 2025
NORGES BANK5.33%2,882,64724.99MDec 30, 2025
Enavate Sciences Gp, LLC 4.55%2,459,70321.33MDec 30, 2025

Fund ownership

UPB fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,443,02512.51MDec 30, 2025
Fidelity Securities Fund-Fidelity Small Cap Growth Fund2.54%1,371,37211.89MDec 30, 2025
Fidelity Select Portfolios-Select Health Care Portfolio1.48%800,0006.94MJan 30, 2026
iShares Trust-iShares Russell 2000 ETF1.44%780,2616.76MJan 30, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund1.28%691,0035.99MJan 30, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund1.26%682,0185.91MDec 30, 2025